Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Pharmaceutical Mid-Term Reports Significant Increase In Sales And Profit

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical announced mid-year results, and company sales increased by 31.4 percent to ¥191.7 billion. Oncology drugs such as Avastin (bevacizumab) and Heceptin (trastuzumab) contributed to the results. The sales for the colorectal cancer drug Avastin more than doubled, increased by 116.9 percent to ¥15.4 billion. The sales for HER2 positive breast cancer drug Heceptin increased by 50 percent to ¥14.7 billion. Chugai's oncology business as a whole grew by 31.4 percent to ¥57.8 billion. In Japan, Chugai leads the pack and accounts for 17.4 percent of cancer drug sales, a 1.6 percent increase compared to last year. Another major area for Chugai is Actemra (tocilizumab), the sales for the monoclonal antibody drug approved to treat rheumatoid arthritis increased six fold to ¥5.3 billion. Except flu drug Tamiflu (oseltamivir) which saw 16 fold increase due to policy stockpile, Chugai group sales grew by 12.1 percent to ¥160.6 billion, and net profit increased by 39 percent to 26.3 billion. The company also raised whole year estimates. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072616

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel